Facts about Manuel

2012, Dec, 05 | MANUEL - SA & more | 0 comments

Manuel

Original text language: English
Responsible for the information: Charlotte Steneloo & Mikael Edlund
Author: Charlotte Steneloo

Issues

  • Sebaceous Adenitis (biopsy positive) December 2012
  • A vast amount of side effects to Cyclosporine (note 2020 August 20th – more information will come)

Akita/Akita-Inu

(In Sweden the japanese Akita = Akita)

Name on pedigree: Kakushigtoto Shun’You Kensha

Registration number: S57970/2006

Date of birth: 7th of April 2006

Date of death: 17th of January 2019

Full pedigree: Akita pedigree,
Swedish Kennel club database

HD/AD/ED:
HD = A (possible in Sweden are: A, B, C, D, E)
AD/ED = no remarks at age 1 year and 4 months.

Eyes: Clear 2007 and 2009

Blood sample sent for research (SA): Yes

Offspring:

Full pedigree

Akita pedigree,
Swedish Kennel club database

HD/AD/ED:
HD = A (possible in Sweden are: A, B, C, D, E)
AD/ED = no remarks at age 1 year and 4 months.

Eyes: Clear 2007 and 2009

Blood sample sent for research (SA): Yes

Offspring:

Manuel's Dog Genetic Diversity test

For those of you who are interested in genetics, you will find Manuel’s result from the Dog Genetic Diversity test here (Veterinary Genetics Laboratory)

Last updated: 2020 20th of August

Charlotte Steneloo

Charlotte Steneloo

Akita owner from Sweden working for openness regarding health issues. One of the founders of Akita-Unleashed. I consider "experience" to be good, that is - if you have opened your mind for change and actually have learnt something, otherwise claiming you are "experienced" means nothing to me... I dare you.

About comments

We love if you want to comment. However, as there is a lot of spam be sure to write something that make us see it is not a spam. If you write “nice website I am always looking for new articles” we might consider that as a spam as it doesn’t refer to anythong written in the post.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Shares
Share This